These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14761246)

  • 1. Toxicity and potency evaluation of pertussis vaccines.
    Corbel MJ; Xing DK
    Expert Rev Vaccines; 2004 Feb; 3(1):89-101. PubMed ID: 14761246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular aspects of Bordetella pertussis pathogenesis.
    Locht C
    Int Microbiol; 1999 Sep; 2(3):137-44. PubMed ID: 10943406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The development of a new generation of pertussis vaccine].
    Chuprinina RP; Bychenko BD; Smirnov VD; Maksiutov RV; Eglit IuKh
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Oct; (10):89-94. PubMed ID: 2075771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines.
    Xing D; Maes A; Behr-Gross ME; Costanzo A; Daas A; Buchheit KH
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):51-63. PubMed ID: 20223190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-cell pertussis vaccine potency assays: the Kendrick test and alternative assays.
    Xing D; Markey K; Das RG; Feavers I
    Expert Rev Vaccines; 2014 Oct; 13(10):1175-82. PubMed ID: 25182836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collaborative study on a Guinea pig serological method for the assay of acellular pertussis vaccines.
    Winsnes R; Sesardic D; Daas A; Terao E; Behr-Gross ME
    Pharmeur Bio Sci Notes; 2009 Oct; 2009(1):27-40. PubMed ID: 20144450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
    Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
    Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of toxicities of acellular pertussis vaccine with whole cell pertussis vaccine in experimental animals.
    Sato Y; Sato H
    Dev Biol Stand; 1991; 73():251-62. PubMed ID: 1778317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
    Gupta RK; Saxena SN; Sharma SB; Ahuja S
    Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
    Storsaeter J; Hallander HO; Gustafsson L; Olin P
    Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative toxicity, protective, histamine sensitizing and leucocytosis promoting activities in mice of Bordetella pertussis culture fluid, bacterial cells and cell extracts.
    Megret F; Fournier JM; Alouf JE
    Med Microbiol Immunol; 1984; 173(4):225-32. PubMed ID: 6096686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and potency of an acellular pertussis vaccine composed of pertussis toxin, filamentous hemagglutinin, and pertactin.
    Sheu GC; Wo YY; Yao SM; Chou FY; Hsu TC; Ju CL; Cheng Y; Chang SN; Lu CH
    J Microbiol Immunol Infect; 2001 Dec; 34(4):243-51. PubMed ID: 11825003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathogenesis of Bordetella pertussis].
    Endoh M; Nagai M; Nakase Y
    Nihon Saikingaku Zasshi; 1991 Nov; 46(6):909-19. PubMed ID: 1687154
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative biological activities of acellular pertussis vaccines produced by Kitasato.
    Watanabe M; Izumiya K; Sato T; Yoshino K; Nakagawa N; Ohoishi M; Hoshino M
    Kitasato Arch Exp Med; 1991 Apr; 64(1):31-42. PubMed ID: 1798236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of the status of acellular pertussis vaccines in practice.
    Lopez AL; Blumberg DA
    Drugs; 1997 Aug; 54(2):189-96. PubMed ID: 9257078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bordetella filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential.
    Scheller EV; Cotter PA
    Pathog Dis; 2015 Nov; 73(8):ftv079. PubMed ID: 26416077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
    Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
    J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children.
    Halperin SA; Barreto L; Friesen B; Meekison W
    Arch Pediatr Adolesc Med; 1994 May; 148(5):495-502. PubMed ID: 7910089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pertussis toxin on the induction of nitric oxide synthesis in murine macrophages and on protection in vivo.
    Xing DK; Canthaboo C; Corbel MJ
    Vaccine; 2000 Apr; 18(20):2110-9. PubMed ID: 10715525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
    Novotny P; Chubb AP; Cownley K; Charles IG
    Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.